What Rajani Treats: Main Uses and Benefits

Rajani is commonly used as a reliable method for long-term pregnancy prevention. This therapeutic domain is applied across areas where additional symptomatic support is needed for menstrual cycle management. It helps manage symptom clusters like irregular periods, heavy blood loss, and painful cramping, which may assist with maintaining functional stability.

The core therapeutic domains involve symptomatic support across clusters associated with pregnancy prevention, PMDD, moderate acne, and a need for folate support. This medication is applied across domains where relief for cyclical and hormonally-driven symptoms is needed. It is used to address pronounced, recurrent emotional and physical symptoms, and may assist with managing moderate acne vulgaris in applicable patients.

The inclusion of Levomefolate calcium is applied in the context of nutritional support to address a critical public health recommendation. This provides a supportive benefit, and plays a role in managing symptoms related to nutritional status for women of childbearing potential.

---

Quick Fact: Support for Symptoms Associated with PMDD
Symptom Category	Symptoms related to heightened physiological activity, including severe cyclical mood symptoms (anxiety, irritability, depression) and physical discomfort (bloating).
Therapeutic Benefit	Contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability during symptomatic phases.

Who Can and Cannot Use Rajani? (Official Eligibility Rules)

Rajani is officially approved for use by females of reproductive age for the purpose of contraception, as well as for treating moderate acne (in females at least 14 years old who have achieved menarche) and symptoms of PMDD.

However, official regulatory labeling establishes a number of absolute contraindications that prohibit its use.

Contraindicated Conditions
Thrombotic Risk: Current or history of blood clots (DVT, PE, stroke, MI) or known thrombophilias.
Vascular Disease: Uncontrolled hypertension, severe dyslipidemias, or diabetes with vascular damage.
Organ Dysfunction: Severe renal impairment, liver disease (including tumors), or adrenal insufficiency.
Hormone-Sensitive Cancers: Known or suspected breast cancer or other estrogen-dependent neoplasia.
Other: Migraine with aura; undiagnosed abnormal uterine bleeding; pregnancy.

Use is not indicated for postmenopausal women and safety has not been established for females prior to the start of menstruation (pre-menarche). It is not recommended during breastfeeding. Females with mild to moderate renal impairment require close monitoring for high potassium levels during treatment.

Interactions with other medicines and products

Official regulatory information for Rajani (Drospirenone, Ethinyl Estradiol, Levomefolate calcium) addresses specific pharmacokinetic and pharmacodynamic interactions.

Contraindicated Combinations and Substances

Co-administration with specific Hepatitis C virus (HCV) drug regimens containing ombitasvir, paritaprevir/ritonavir, with or without dasabuvir, is formally contraindicated. Additionally, Rajani is contraindicated in females who are over 35 years of age and smoke, due to a significantly increased risk of serious cardiovascular events.

Clinically Significant Drug Interactions

Interaction Type	Interacting Agents / Classes	Restriction or Constraint
Hormonal Effectiveness	Enzyme Inducers (e.g., CYP3A4 Inducers, St. John's wort)	Requires use of a back-up or alternative method of contraception to maintain efficacy.
Hyperkalemia Risk (Pharmacodynamic)	Potassium-Increasing Drugs (e.g., ACE inhibitors, Potassium-Sparing Diuretics, long-term NSAIDs)	Requires serum potassium concentration monitoring during the first treatment cycle in high-risk patients.
Exposure Modification (Pharmacokinetic)	Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Clarithromycin)	May increase Drospirenone exposure, contributing to hyperkalemia risk in high-risk patients, requiring monitoring.
Folate Metabolism	Antifolate Drugs (e.g., Methotrexate, Pyrimethamine)	The Levomefolate component may decrease the pharmacological effect of the co-administered antifolate drug.

Population-Specific Notes

The risk of hyperkalemia during co-administration with potassium-increasing drugs or CYP3A4 inhibitors is heightened in females with pre-existing conditions that predispose to high potassium, such as renal impairment, hepatic impairment, or adrenal insufficiency.

Rajani is a combination product containing an estrogenic component and a progestin component, drospirenone.

Estrogenic and Progestin Components

The estrogenic and progestin components modulate the hypothalamic-pituitary-ovarian axis. The primary mechanism is the suppression of gonadotropins, specifically Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH), via a negative feedback loop on the pituitary gland. This downstream effect prevents follicular maturation and inhibits the surge of LH required for ovulation, thus precluding ovum release from the ovary.

Drospirenone-Specific Interactions

Drospirenone acts as a progesterone receptor agonist to contribute to the central suppression of gonadotropins and alters the consistency of cervical mucus, rendering it less permeable to sperm. Drospirenone also functions as an antagonist at the mineralocorticoid receptor (MR), similar to spironolactone. This interaction reduces the binding of aldosterone to its receptor in the renal distal tubules, promoting the excretion of sodium and water. Furthermore, drospirenone exhibits antagonistic activity at the androgen receptor, modulating androgenic signaling pathways in target tissues by competing for receptor binding.

How to Use Rajani

Rajani is administered as a continuous, 28-day cyclic regimen. This protocol defines the precise sequence and timing for the long-term use of the oral tablet.

---

Official Administration Guidelines

Category	Instruction
Route of administration	Oral (swallowed).
Dosing schedule	One tablet daily for 28 consecutive days. The cycle consists of 24 active tablets (containing 3 mg Drospirenone and 0.02 mg Ethinyl Estradiol plus Levomefolate calcium) followed by 4 tablets containing only Levomefolate calcium or inactive components.
Timing	The tablet is taken once daily at the same time every day, often after the evening meal or at bedtime to aid consistency. Administration may occur with or without food.
Procedural Conditions	Tablets must be consumed in the exact order directed on the blister pack to maintain the correct hormonal sequence throughout the 28-day period. Use is specified for postpubertal women who are at least 14 years of age for certain approved indications.
Special Rules	A non-hormonal back-up contraceptive method must be used during the first 7 consecutive days of the first cycle if the tablet is initiated later than the first day of the menstrual cycle. Severe vomiting or diarrhea shortly after administration is considered a missed dose.

Procedural Structure

This regimen requires strict adherence to the 24/4 cyclic structure, which involves the sequential intake of 24 active hormonal tablets followed by the final 4 tablets. The protocol ensures that the hormonal and supplemental components are delivered in the precise order and concentration required, and a new 28-day pack must be started immediately following the last tablet of the previous cycle.

Research Evidence / Overview of Studies for Rajani

---

## Evidence for use in Preventing Pregnancy (Contraception)

Research supporting the primary purpose of Rajani is based on established methods used for regulatory review of all combined hormonal contraceptives. These include large-scale Randomized Controlled Trials (RCTs) conducted over approximately one year, as well as long-term observational studies that monitor the use patterns of the hormonal components (Drospirenone and Ethinyl Estradiol).

Studies were conducted in generally healthy women of reproductive potential, and researchers examined contraceptive efficacy, using the standardized measure of the Pearl Index (rate of unintended pregnancy). The findings derived from these trials and ongoing monitoring are considered well-established, supporting the evidence base for contraceptive use when the product is used as directed.

---

## Research on Symptom Management for Premenstrual Dysphoric Disorder (PMDD)

Rajani was studied for outcomes related to pronounced, disruptive symptoms of Premenstrual Dysphoric Disorder (PMDD) in women who also desire contraception. Research included dedicated, short-term, placebo-controlled trials, where patient groups were assigned either the medication or an inactive placebo.

Researchers monitored outcomes related to outcomes related to physical discomfort (such as bloating) and outcomes describing episodic or acute changes in mood and behavior (like irritability and anxiety) using standardized tools like the Daily Record of Severity of Problems (DRSP) scale. The research describes measurements of change in symptom severity during the study period. These studies also documented a significant placebo effect, which is relevant in evidence describing how symptoms are measured.

---

## Clinical Studies for Moderate Acne Vulgaris

Research examined outcomes related to inflammatory and irritative states of the skin over defined time intervals. These controlled studies observed responses over a period of at least six menstrual cycles, examining short-term changes measured during the study. Outcomes were assessed using two methods: measuring the number of inflammatory and non-inflammatory lesions and utilizing the Investigator Global Assessment (IGA), a standardized scale used by clinicians to judge the overall appearance of the skin.

Studies showed patterns related to changes in these scores and lesion counts, indicating patterns observed during the trial duration. Research so far remains focused on women presenting with moderate acne severity, and comparative evidence is lacking for how this combination relates to non-hormonal treatments for acne.

---

## Folate Supplementation and Neural Tube Defect Risk

Research in this area consisted of specialized pharmacokinetic studies that measured the absorption and utilization of the Levomefolate Calcium component. Studies monitored the Red Blood Cell (RBC) folate concentration, which is used to monitor the body’s long-term folate status. These studies showed patterns related to elevated RBC folate levels.

Evidence contributes to understanding that the component may be associated with folate status that aligns with public health recommendations, which aim to reduce the risk of a neural tube defect in a pregnancy conceived while or shortly after using the product. However, it is critical to note that no clinical trial has been conducted using this specific combination product to directly measure the actual incidence rate of neural tube defects (NTDs).

Key Studies & References Cochrane Review on Drospirenone/Ethinyl Estradiol for Premenstrual Syndrome (PMS) and Premenstrual Dysphoric Disorder (PMDD)

Common questions about Rajani (FAQ)

Q: Is Rajani a long-term treatment or short-term?

Rajani is administered as a continuous, 28-day cyclic oral regimen. This administration protocol is established by regulatory bodies and indicates the product’s role for long-term use. Therefore, it is generally intended as an ongoing course of treatment for contraception and other approved chronic conditions like PMDD and moderate acne.

Q: What is the difference between Rajani and similar medicines I see advertised?

Rajani is a combination oral contraceptive that contains drospirenone, a progestin component. Official regulatory information notes drospirenone for its anti-mineralocorticoid activity and anti-androgen effects. This specific pharmacological profile is what differentiates it from combined oral contraceptives that utilize older or different progestin components.

Q: Are there common foods I should avoid while taking Rajani?

Official regulatory documents caution against the use of grapefruit or grapefruit juice while using this medication. This is because these substances may increase the blood levels of the estrogen component. This concern is noted because it could potentially raise the risk or severity of related side effects.

Q: Are there any specific lifestyle changes recommended when on Rajani?

Rajani is officially contraindicated in women over 35 who smoke, as this lifestyle factor significantly increases the risk of serious cardiovascular events. Additionally, maintaining consistent daily timing for administration is important for supporting the medication’s intended contraceptive efficacy.

Q: What should I do if I think I'm having a serious side effect from Rajani?

If you experience symptoms that suggest a serious adverse reaction, such as signs of a blood clot, regulatory guidance states that individuals should immediately discontinue the drug and seek emergency medical attention. This procedure is critical for addressing rare, serious vascular risks associated with this class of medicine.

Q: Why do doctors prefer Rajani over older medicines?

Newer formulations that contain drospirenone are sometimes utilized because this specific progestin component is described as having a distinctive pharmacological profile. Official studies indicate that drospirenone may be associated with a lower incidence of certain hormone-related adverse effects, such as breast tenderness or mood changes, when compared to older progestins.

Q: Does Rajani have any known interactions with grapefruit juice?

Yes, official regulatory information confirms an interaction concern with grapefruit juice. Consuming grapefruit juice may increase the estrogen component's concentration in the bloodstream. This increase is a concern because it could potentially raise the risk of developing estrogen-related side effects.

Q: How quickly does Rajani start working?

The onset of contraceptive protection depends on when the medication is started. If Rajani is initiated later than the first day of the menstrual cycle, regulatory instructions describe the need for a non-hormonal back-up method. This back-up is necessary until the active tablets have been taken for 7 consecutive days to support contraceptive effectiveness.

Q: What happens if I miss a dose of Rajani?

Official drug information provides detailed instructions for dealing with missed doses. The appropriate procedure varies based on whether an active tablet or an inactive tablet was missed, and how many were missed in a row. Adhering to these instructions is important, as a missed dose may compromise the drug’s effectiveness and require the temporary use of back-up contraception.

Q: How long does the effect of Rajani usually last?

Rajani is intended as a once-daily tablet, and its contraceptive effect is continuous. The drug’s effectiveness is maintained by consistently taking a pill at the same time every day. This consistency ensures the hormone levels remain steady throughout the 28-day cycle to continuously suppress ovulation.

Q: Is Rajani considered a controlled substance?

No, Rajani is classified as a prescription-only medication. Official regulatory classification confirms that it is not considered to be a controlled substance.

Q: Are there any restrictions on alcohol consumption while taking Rajani?

Regulatory documents note a minor interaction between the estrogen component in Rajani (Ethinyl Estradiol) and alcohol. However, official prescribing information does not list alcohol as a formal contraindication or major restriction for use.

Q: Is Rajani available as a generic medicine?

Yes, the combination of active ingredients in Rajani (drospirenone, ethinyl estradiol, and levomefolate calcium) is an established formulation. Official records indicate that this combination is available as a generic medicine.

Q: Can Rajani affect the results of lab tests?

Yes, official warnings and precautions note that the use of oral contraceptives may influence the results of certain laboratory tests. These include tests for blood clotting, lipid levels, glucose tolerance, and the function of the liver, thyroid, adrenal, and kidney systems.

Q: Is Rajani addictive?

No, Rajani is a hormonal medication. Official pharmacological classification confirms that the drug is not associated with the development of drug dependence or addiction.

Q: Is it possible to be allergic to Rajani?

Yes, like any pharmaceutical product, Rajani is contraindicated (meaning its use is prohibited) in individuals who have a known hypersensitivity or allergy to any of the active or inactive components listed in the formulation.

Q: Does Rajani have a withdrawal period if stopped?

Rajani is not associated with a formal drug withdrawal syndrome or dependence, according to official adverse reaction data. Following discontinuation, the body is typically followed by a return to its natural menstrual cycle and ovulatory function.

Q: Does the efficacy of Rajani change over time?

Clinical studies indicate that the contraceptive effectiveness of Rajani is reliable and stable over long-term use. This stability is dependent on the medication being taken correctly and consistently as directed by the prescribed schedule.

Q: Is it okay to crush or split Rajani tablets?

Official product information states that the film-coated tablets should be swallowed whole, in the proper order as directed on the blister pack. Crushing, splitting, or chewing is not described or recommended in the administration guidelines.

Q: Is Rajani a new or established drug?

The combination of active ingredients contained in Rajani is an established medication. Official records indicate that the formulation was first approved by the FDA in the early 2000s.

How to Store and Dispose of Rajani?

The storage and disposal of Rajani (Drospirenone, Ethinyl Estradiol, and Levomefolate Calcium) must adhere strictly to regulatory requirements to preserve product quality and safety.

---

Storage Conditions

Rajani must be stored at Controlled Room Temperature (CRT), defined as 20°C to 25°C (68°F to 77°F), with permitted excursions up to 30°C (86°F). The tablets must be protected from light and moisture and kept in the original blister packaging; do not freeze the medication. As with all prescription medicines, Rajani must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Rajani should be discarded via an authorized drug take-back program or by following secure household disposal procedures. The medication must not be flushed down the toilet or poured into any drain.